- Pure Extracts Technologies Corp (PULL) provides some key points to the public for its corporate update
- Pure is proud to report that there have been no cases of Covid-19 at its facility despite its proximity to Whistler Village
- Its Pemberton, BC facility is fully operational and in daily production and readily able to meet the increasing demand for gummies, vapes and white label products
- It is concurrently working towards scalable entry into the US market via a Michigan-based joint venture
- Pure Extracts Technology Corp. features a processing facility located just 20 minutes north of the world-famous Whistler, British Columbia
- Pure Extracts Technologies Corp (PULL) is up 3.95 per cent and is trading at C$0.40 at 10:17 am
Pure Extracts Technologies Corp (PULL) provides some key points to the public for its corporate update.
Pure is pleased to report that even though the Covid-19 pandemic continues to impact numerous business operations and even society itself, its enterprise has not only survived but is thriving and growing.
With the early adoption of workplace anti-viral protocols in place, Pure is proud to report that there have been no cases of Covid-19 at its facility despite its proximity to Whistler Village which has been hard hit by the pandemic.
As Pure heads into the Spring, and hopes for an end to the pandemic builds, it decided to offer a few points of interest regarding its growing business.
Its Pemberton, BC facility is fully operational and in daily production and readily able to meet the increasing demand for gummies, vapes and white label products.
It is concurrently working towards scalable entry into the US market via a Michigan-based joint venture which proposes to include strategically located equipment and processing operations within the state.
Pures’ involvement in the functional and psychoactive mushrooms space is also gaining momentum.
Pure has successfully launched its functional wellness line of products through its Pure Mushrooms branded Amazon direct-to-consumer sales channels in the US and Canada.
Pure believe’s Pure Mushrooms can be a meaningful revenue generator in 2022 and that entering the functional part of the mushrooms sector will give them greater ability to develop meaningful psilocybin-based psychedelic formulations in future.
Regarding our outlook for psychoactive mushroom compounds, Pure continues to actively move forward with R&D efforts in this area.
Pure is not alone in finding it hard to obtain psychedelic biomass as it is highly regulated by Health Canada with many people reporting that there is little or no product available for R&D purposes.
Fortunately, it has entered an agreement with ShroomBloom, a BC-based psychedelic mushroom cultivator, to assist in providing Pure with ample product for our R&D efforts upon final receipt of its Health Canada approvals.
Pure is also excited to be working with Psyence Group (CSE:PSYG) who offers very strong R&D and production capabilities.
It currently has clinical trial opportunities in two major Canadian universities for the use of psilocybin in palliative care, and through its JV it will have access to Psyence’s team of doctors and researchers in Toronto, South Africa and Jamaica.
This additional effort will prove invaluable as Pure works to formulate a psilocybin compound that will be fast-acting and effective in dealing with PTSD, anxiety and other mental illnesses.
Although Covid-19 has lengthened its sales cycle somewhat, it is now enjoying renewed interest from producers and brands looking for new opportunities and partnerships.
Pure continues to be excited to be working together to unlock the potential value of what could soon be a continent-wide industry and an opportunity totally unique to our lifetime.
Pure Extracts Technology Corp. features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia.
Pure Extracts Technologies Corp (PULL) is up 3.95 per cent and is trading at C$0.40 at 10:17 am ET.
